Cisplatin, Vinblastine, Bleomycin併用化学療法(PVB療法)を行った進行性精巣腫瘍の治療成績とRisk criteriaの検討

概要

論文の詳細を見る
PVB療法の治療成績はCR 50.0%を含む奏効率87.5%と他施設とほぼ同様の成績であった.又,Indiana・EORTC・NCI・MSKCCの四つのcriteriaを比較すると,accuracyではMSKCCが最も優れていたが,sensitivityではEORTCが最も優れていたBetween 1982 and 1991, 24 patients with advanced testicular germ cell tumor were treated by combination chemotherapy with cisplatin, vinblastine and bleomycin (PVB). Based on short-term efficacy of the PVB regimen and long-term prognosis in our patients, we evaluated 4 risk criteria proposed by Indiana University, National Cancer Institute (NCI), Memorial Sloan-Kettering Cancer Center (MSKCC) and European Organization for Research and Treatment of Cancer (EORTC). Clinical staging were IIA in 8 patients, IIB in 8, IIIA in 1, IIIB in 5 and IIIC in 2. Metastases included retroperitoneal lymph node in 20 cases (> 5 cm in 10), lung in 6, bone and liver in each 1. Complete response (CR) was obtained in 12 (50%) patients and partial response (PR) in 9 (38%). According to the stage and metastatic site, CR was achieved in 75%, 38% and 38%of the stage IIA, IIB and III tumors, respectively, and in 60% and 50% of retroperitoneal and pulmonary metastases, respectively. However, neither CR nor PR was recognized for live and bone metastases. Prognosis was assessed with a mean followup period of 88.5 months. Although all 12 patients with CR were alive, 4 of the 9 with PR and all patients on whom the drug was ineffective died of cancer. Accuracy in predicting prognosis was 82%, 75%, 74%, and 63% using the MSKCC, Indiana, NCI and EORTC risk criteria, respectively.

Cisplatin, Vinblastine, Bleomycin併用化学療法(PVB療法)を行った進行性精巣腫瘍の治療成績とRisk criteriaの検討

スポンサーリンク

概要

著者

関連論文

スポンサーリンク